DOP2021000081A - Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3 - Google Patents

Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3

Info

Publication number
DOP2021000081A
DOP2021000081A DO2021000081A DO2021000081A DOP2021000081A DO P2021000081 A DOP2021000081 A DO P2021000081A DO 2021000081 A DO2021000081 A DO 2021000081A DO 2021000081 A DO2021000081 A DO 2021000081A DO P2021000081 A DOP2021000081 A DO P2021000081A
Authority
DO
Dominican Republic
Prior art keywords
potassium channels
arylsulfonylpirrolcarboxamide
activators
derivatives
compounds
Prior art date
Application number
DO2021000081A
Other languages
English (en)
Inventor
Graven Sams Anette
Kyhn Rasmussen Lars
Yu Wanwan
Robert Fleming Paul
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of DOP2021000081A publication Critical patent/DOP2021000081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos novedosos que activan los canales de potasio Kv3. Los compuestos tienen la estructura Aspectos separados de la invención se refieren a composiciones farmacéuticas que comprenden dichos compuestos y el uso de los compuestos para tratar trastornos que responden a la activación de los canales de potasio Kv3.
DO2021000081A 2018-10-30 2021-04-29 Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3 DOP2021000081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201800787 2018-10-30
PCT/EP2019/079587 WO2020089262A1 (en) 2018-10-30 2019-10-30 Arylsulfonylpyrolecarboxamide derivatives as kv3 potassium channel activators

Publications (1)

Publication Number Publication Date
DOP2021000081A true DOP2021000081A (es) 2021-07-30

Family

ID=70327875

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2021000081A DOP2021000081A (es) 2018-10-30 2021-04-29 Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3

Country Status (23)

Country Link
US (1) US20200131156A1 (es)
EP (1) EP3873891A1 (es)
JP (1) JP2022509416A (es)
KR (1) KR20210086661A (es)
CN (1) CN113056461A (es)
AR (1) AR116898A1 (es)
AU (1) AU2019373367A1 (es)
BR (1) BR112020013011A2 (es)
CA (1) CA3116273A1 (es)
CL (1) CL2021001123A1 (es)
CO (1) CO2021005579A2 (es)
CR (1) CR20210285A (es)
DO (1) DOP2021000081A (es)
EA (1) EA202190899A1 (es)
EC (1) ECSP21038534A (es)
IL (1) IL282639A (es)
JO (1) JOP20210091A1 (es)
MA (1) MA54061A (es)
MX (1) MX2021004935A (es)
PE (1) PE20211975A1 (es)
SG (1) SG11202104348XA (es)
TW (1) TW202031645A (es)
WO (1) WO2020089262A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024530208A (ja) 2021-08-10 2024-08-16 アウトイフオンイ トヘラペウトイクス リミテッド カリウムチャネルモジュレーター
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100179203A1 (en) * 2007-07-04 2010-07-15 Antonio Nardi Novel pyrazole derivatives useful as potassium channel modulators
TW201028421A (en) * 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
WO2011073269A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Piperidine aryl sulfonamide derivatives as kv1.3 modulators
WO2011073276A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
FR2967674B1 (fr) * 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
NZ628762A (en) * 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
JP6240667B2 (ja) * 2012-05-22 2017-11-29 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのトリアゾール
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
AU2019373367A1 (en) 2021-05-27
SG11202104348XA (en) 2021-05-28
MX2021004935A (es) 2021-06-08
TW202031645A (zh) 2020-09-01
WO2020089262A1 (en) 2020-05-07
EA202190899A1 (ru) 2021-08-19
CR20210285A (es) 2021-09-16
CN113056461A (zh) 2021-06-29
JP2022509416A (ja) 2022-01-20
MA54061A (fr) 2021-12-15
EP3873891A1 (en) 2021-09-08
IL282639A (en) 2021-06-30
PE20211975A1 (es) 2021-10-05
ECSP21038534A (es) 2021-06-30
KR20210086661A (ko) 2021-07-08
CO2021005579A2 (es) 2021-05-10
CL2021001123A1 (es) 2021-10-22
AR116898A1 (es) 2021-06-23
CA3116273A1 (en) 2020-05-07
JOP20210091A1 (ar) 2023-01-30
US20200131156A1 (en) 2020-04-30
BR112020013011A2 (pt) 2021-05-04

Similar Documents

Publication Publication Date Title
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
DOP2019000040A (es) Compuestos de pirrolizina sustituidas y usos de los mismos
CO2018008707A2 (es) Inhibidores de la proteína quinasa 1 que interactúa con el receptor
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
DOP2017000298A (es) Reguladores de nrf2
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
CL2017001124A1 (es) Agentes inmunomoduladores
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CL2015002083A1 (es) Composiciones herbicidas sinergicas
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CL2019003430A1 (es) Tratamiento conjunto antineoplásico.
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2018001837A1 (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
UY36166A (es) Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico
UY36195A (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
DOP2021000081A (es) Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t